For the quarter ending 2026-03-31, SUPN made $207,705K in revenue. -$2,293K in net income. Net profit margin of -1.10%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 207,705 | 211,572 | 192,103 | 165,453 |
| Cost of revenues | 23,391 | 23,007 | 18,965 | 16,827 |
| Research and development | 39,438 | 27,827 | 29,366 | 22,115 |
| Selling, general and administrative | 125,173 | 122,390 | 179,678 | 93,551 |
| Amortization of intangible assets | 25,644 | 24,526 | 24,325 | 20,819 |
| Intangible asset impairment charges | - | 0 | - | - |
| Contingent consideration loss | 2,391 | 17,759 | 0 | 0 |
| Total costs and expenses | 216,037 | 215,509 | 252,334 | 153,312 |
| Operating loss | -8,332 | -3,937 | -60,231 | 12,141 |
| Interest and other income, net | 2,382 | 2,023 | 2,277 | 4,528 |
| Interest expense | - | 0 | - | - |
| Total other income (expense), net | 2,382 | 2,023 | 2,277 | 4,528 |
| Loss before income taxes | -5,950 | -1,914 | -57,954 | 16,669 |
| Income tax expense (benefit) | -3,657 | 2,191 | -12,837 | -5,830 |
| Net loss | -2,293 | -4,105 | -45,117 | 22,499 |
| Basic EPS | -0.04 | -0.072 | -0.8 | 0.4 |
| Diluted EPS | -0.04 | -0.072 | -0.8 | 0.4 |
| Basic Average Shares | 57,647,548 | 57,362,340 | 56,552,741 | 56,024,771 |
| Diluted Average Shares | 57,647,548 | 56,743,922 | 56,552,741 | 56,643,189 |
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)